Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance

International Journal of Gynecological Cancer

Volumn 24, Issue 8, 2014, Pages 1381-1388

  Li, Bing ^a   Chen, Hong ^a   Wu, Nan ^a   Zhang, Wen Jing ^a   Shang, Li Xin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ABCC5; Bmi 1; Cisplatin; Epithelial ovarian cancer; miR 128

Indexed keywords

BMI1 PROTEIN; CISPLATIN; MESSENGER RNA; MICRORNA; MICRORNA 128; MULTIDRUG RESISTANCE PROTEIN 5; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN128 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; NUDE MOUSE; OVARIAN NEOPLASMS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84925615729     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000252     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
3. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
5. Li Y, VandenBoom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-6712.
6. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem . 2008;283:29897-29903.
7. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell. 2003;115:787-798.
8. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495-500.
9. Rossi S, Sevignani C, Nnadi SC, et al. Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome. 2008;19:526-540.
10. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1-9.
11. Meng F, Henson R, Wehbe-Janek H, et al. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007;282:8256-8264.
12. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67:11111-11116.
13. Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111:478-486.
14. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334:1351-1358.
15. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68:9125-9130.
16. Zhu Y, Yu F, Jiao Y, et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011;17:7105-7115.
17. van Lohuizen M, Verbeek S, Scheijen B, et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65:737-752.
18. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61:2409-2412.
19. Kim JH, Yoon SY, Jeong SH, et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004;13:383-388.
20. Qin ZK, Yang JA, Ye YL, et al. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer. 2009;9:61.
21. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281-290.
22. Mourskaia AA, Amir E, Dong Z, et al. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res. 2012;14:R149.